<DOC>
	<DOCNO>NCT00006040</DOCNO>
	<brief_summary>RATIONALE : Radiolabeled monoclonal antibody locate cancer cell deliver radiation without harm normal cell . Drugs use chemotherapy use different way stop cancer cell divide stop grow die . Peripheral stem cell transplantation may allow doctor give high dos radiation chemotherapy drug kill cancer cell . PURPOSE : Phase I trial study effectiveness radiolabeled monoclonal antibody therapy plus etoposide follow peripheral stem cell transplantation treat patient advanced myelodysplastic syndrome refractory leukemia .</brief_summary>
	<brief_title>Radiolabeled Monoclonal Antibody Therapy Etoposide Followed Peripheral Stem Cell Transplantation Treating Patients With Advanced Myelodysplastic Syndrome Refractory Leukemia</brief_title>
	<detailed_description>OBJECTIVES : - Determine maximum tolerate dose yttrium Y 90 humanize monoclonal antibody M195 combine etoposide preparative regimen autologous peripheral blood stem cell transplantation patient advance myelodysplastic syndrome refractory leukemia . - Determine qualitative toxicity associate regimen patient population . - Assess preliminary information engraftment follow condition regimen patient . OUTLINE : This dose escalation study yttrium Y 90 humanize monoclonal antibody M195 ( Y90 MOAB M195 ) . Patients receive Y90 MOAB M195 IV 40 minute day -12 -9 etoposide IV several hour day -3 . Peripheral blood stem cell bone marrow reinfused day 0 . Patients receive filgrastim ( G-CSF ) subcutaneously begin day 1 hematopoietic recovery . Cohorts 3-6 patient receive escalate dos Y90 MOAB M195 maximum tolerate dose ( MTD ) determine . The MTD define dose precede 3 6 patient experience dose limit toxicity . Patients follow day 10 14 monthly 6 month . PROJECTED ACCRUAL : A total 3-24 patient accrue study within 12 month .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : One follow diagnosis : Acute myeloid leukemia Accelerated/blastic phase myeloproliferative disorder ( i.e. , great 10 % blast bone marrow presence extramedullary disease ) Myelodysplastic syndrome Acute lymphocytic leukemia expression CD33 Greater 20 % blast population No evidence CNS disease Relapsed previously achieve complete remission Must previously peripheral blood stem cell bone marrow cell harvest cryopreserved remission Greater 25 % bone marrow blast must CD33 positive PATIENT CHARACTERISTICS : Age : 18 Performance status : Not specify Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Not specify Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 60 mL/min Cardiovascular : LVEF great 50 % ECG MUGA No history cardiomyopathy symptomatic congestive heart failure Pulmonary : DLCO least 50 % predict Other : Not pregnant nursing Negative pregnancy test HIV negative No concurrent active malignancy No known sensitivity E. coli derive product PRIOR CONCURRENT THERAPY : Biologic therapy See Disease Characteristics Chemotherapy See Disease Characteristics Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>atypical chronic myeloid leukemia , BCR-ABL1 negative</keyword>
	<keyword>myelodysplastic/myeloproliferative neoplasm , unclassifiable</keyword>
</DOC>